Taro chairman Barrie Levitt says Sun’s publication of details of incomplete settlement talks designed to address the parties’ long running acquisition battle violates confidentiality agreements and presents a one-sided view of current events.
King Pharmaceuticals’ $1.6bn (€1.2bn) acquisition of Alpharma heads a busy week of deals that has seen J&J agree to pay $438m for Omrix and India’s Sun further its presence in the US narcotic APIs sector through the purchase of Chattem Chemicals.
Eli Lilly has bought ImClone for around $6bn (€4.6bn), gaining access to the blockbuster cancer therapy Erbitux (cetuximab) and significantly expanding its portfolio of Phase III oncology candidates, including IMC11F8 which is viewed as a potential Erbitux...
Cost cutting has sustained pharma profits in the faltering global economy, however top executives are starting to realise that reducing R&D capacity may not have been the smartest move in an era of weak pipelines and impending patent expiry, according...
Robert Sexauer, CEO of biopharmaceuticals group RCP Therapeutics, says the R&D investment deal signed with FirstPoint Biotech shows the attractiveness of the firm’s nano-medical pipeline, particularly given the current economic climate.
Sanofi-Aventis’ €1.8bn ($2.6bn) offer for Czech generics firm Zentiva has been unanimously accepted by the latter firm’s board after four months of wrangling that has seen the bid increase by 9.5 per cent.
US protein manufacture and development services provider American Peptide Company (APC) says that its parent company, Ito Life Sciences (ILS), is to be acquired by fellow Japanese firm Otsuka Chemical.